Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer By Ogkologos - November 24, 2025 150 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LUNAR study Source RELATED ARTICLESMORE FROM AUTHOR FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic MOST POPULAR Apple Season is Here! October 1, 2021 FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive,... November 20, 2024 ESMO Asia Virtual Congress 2020, 20-22 November October 26, 2020 Giving Myself the Most Time and Best Chance at Beating Cancer:... October 10, 2023 Load more HOT NEWS A tribute to Professor Anne Charlton Our COVID-19 Response: How We’re Supporting Frontline Workers At Revolution Foods Creating a shared vision to detect cancer earlier Tarlatamab Shows Promise in Patients with Previously Treated Small-Cell Lung Cancer
